A new therapy employing viruses that infect bacteria is emerging as a potential solution for chronic infections when antibiotics prove ineffective. This treatment, known as phage therapy, is already accessible over-the-counter in Europe.
David Felstead, who had been undergoing treatment for a superbug infection in his left leg for six years, faced a critical situation when antibiotics ceased to work. His health deteriorated, and the risk of losing his limb became a significant concern. As conventional antibiotics failed, his doctors considered further revision surgery, which had not been effective, or amputation. The advent of phage therapy offered a new avenue for treatment.
Bacteriophages, or phages, are viruses that specifically target and kill bacteria. They work by attaching to a bacterium, injecting their genetic material, and utilizing the bacterium's cellular machinery to replicate themselves. The infected bacterium eventually ruptures, releasing numerous new phages capable of infecting more bacteria. This targeted approach contrasts with broad-spectrum antibiotics, which can also harm beneficial bacteria in the body. Felstead's treatment involved phage therapy, and he is awaiting results to determine its efficacy.
Felstead's case highlights the growing challenge of antibiotic resistance, a global health crisis that renders common infections increasingly difficult to treat. The World Health Organization has identified antimicrobial resistance as one of the top 10 global public health threats facing humanity.
While phage therapy has been used in some regions for decades, its accessibility and regulatory approval vary worldwide. Its availability over-the-counter in Europe represents a significant step in providing alternative treatment options for patients with infections that have become untreatable with conventional antibiotics.